Early Look at the Hammerstone Report (Street Rec's Roundup)
Wednesday, September 3, 14
ABB upgraded neutral to buy
Luxury Goods - downgrade Prada to Underweight and reduce our price target to HKD 46 implying 17% downside. We see a risk to earnings as increasing competition impacts retail performance and causes deleverage…upgrade Hugo Boss to Equal Weight
CONN - price target moves to $40 from $71 amid persistent volatility in the credit business
P - August ad load expands slightly; old and young listeners still lag
ALXN assuming neutral and $179 tgt
BMRN assuming OP and $74 tgt
MDVN assumed OP and $98 tgt
NCT reinstated OP and $16.50 tgt
ARNA assuming UP and $3.50 tgt
OREX assumed OP and $10 tgt
VVUS assumed neutral and $5 tgt
DNDN assumed neutral and $1.50 tgt
SI - reiterate Outperform and tgt Eu115 and remains our top pick in European Capital Goods
QCOM – lower estimates to further account for the impact of non-paying Chinese vendors continuing through 2015
SFG init hold and $67 tgt
CENX init buy and $30 tgt
ALLY init buy and $28 tgt
KEX - believe shares could see continued upside from here (our $145 price target implies 20% potential upside, but cycle peak potentially much higher) given robust strength across Kirby's business segments
Mortgage REITs – defending group (TWO) on yesterday's weakness following FHFA proposal of a draft rule that would eliminate mortgage REITs from having access to FHLB funding.
DGX upgraded to conviction buy list
ALR downgraded neutral to sell – says while growth and margins should improve modestly in 2015, we take a below-consensus view on revenue/EPS for the next few years
SRCL downgraded buy to neutral on valuation
EXAS tgt raised to $26 from $19
Dry Bulk shipping - believe the dry bulk shipping market is poised to strengthen through at least 2015 - SALT init buy and $13 tgt, SBLK init buy and $21 tgt, VLCCF init buy and $15 tgt, GSKNF init buy and $29 tgt
RCL tgt raised to $73 and maintain buy - expect the relative outperformance against CCL (where we maintain our Underperform recommendation) to continue
ARMH – reit OP due to the upcoming iPhone 6 unveiling, the development of fresh internet and credit card security concerns, and recent industry checks that we see increasing the adoption of ARM® TrustZone® technology
EPZM – reit OP and $40 price target after the company announced the resignation of President and CFO, Jason Rhodes
TTPH tgt raised to $20 from $16 - Eravacycline comes in strong in first look at pivotal program, boding well for potential superiority
ASMI downgraded OW to neutral
KERX - believe most investors at this point expect the FDA to approve Zerenex for the treatment of hyperphosphatemia in patients with ESRD, which is likely contributing to the strong recent run in the share price
BDBD upgraded neutral to buy
KSS upgraded hold to buy and raise tgt to $68 from $48
CYS downgraded buy to hold
Telecom industry downgraded to cautious; FTR downgraded EW to UW and AMT downgraded OW to EW due to fair valuation, and overhangs related to international expansion
AVNW upgraded hold to buy
JPM upgraded neutral to buy
BAC downgraded buy to neutral
AAPL - recommend taking profits in AAPL. Unless next week's event details massive incremental profit opportunities, we are likely to downgrade AAPL's rating
Comm Tech - are buyers of EQIX and CCOI as each should benefit from an accelerating trend of enterprises moving to the cloud. EQIX benefits from the growing optionality demand for cloud providers, while CCOI benefits as a result of increased connectivity demands to the cloud
CNQR downgraded OP to neutral
FITB - reiterate our Buy rating and $25 price target as it remains one of the most profitable regional banks in the U.S.
TOL - reiterate our Underperform rating on TOL. F3Q14 EPS exceeded our estimate, but F3Q14 order growth was below our assumptions. We view the shares as fully valued at current levels
Memory/DRAM - believe despite much press commentary out there, our checks indicate NAND-DRAM demand continues to be stable; believe unlike the past history, any pricing softness in NAND-DRAM will be more modest given tight supply control, low inventory implying balanced 2H14-1H15 supply-demand
CHRW downgraded buy to hold
ECHO downgraded hold to sell
CORR upgraded hold to buy
ATHL; notes strong well results update; more catalysts ahead
PCG - Despite the lower estimates, we are raising our PT $3 to $46 on a higher utility multiple and removing the previous -7.5% discount vs peers. We continue to see the current 3% premium PCG trades as unwarranted given the high likelihood of 1-2 years of legal uncertainty
LL upgraded neutral to OP
EXAS - Meetings w/ CEO were informative and mgmt. remains quite confident on their outlook
HMSY - Recent court documents suggest CMS is set to award the Medicare RAC contracts on Oct. 22…continue to view the Medicare RAC awards as a key catalyst for the stock